HuR is an RNA-binding protein, and it stabilizes not only ARE-mRNA, but also mRNA not containing ARE. 6, 7 HuR has three RNA recognition motifs (RRMs), 8 which are highly abundant RNA-binding domains in eukaryotes. 9 The first two RRMs form a cleft that facilitates binding of mRNA 8, [10] [11] [12] and they also interact to form a HuR homodimer. 13 The hinge region between RRM2 and RRM3 contains the nuclear localization signal. 4 RRM3 is important for stabilizing the RNAprotein complex and mediating protein-protein interactions, 12 such as interactions with the poly-A tail of target mRNA. 10 Moreover, it shows terminal adenosyltransferase activity. 14 HuR stabilizes ARE-mRNAs involved in multiple biological events such as carcinogenesis, differentiation, and inflammation. 15, 16 HuR is overexpressed in cancers, such as in oral, colon, ovarian, brain, breast, and pancreatic cancers. [17] [18] [19] [20] [21] [22] [23] In particular, the abundant cytoplasmic expression of HuR is associated with the malignant phenotype of several types of carcinomas. 19 We previously reported that HuR knockdown attenuated the malignant phenotype by inhibiting the stabilization of ARE-mRNA. Inhibition of HuR-ARE interaction can be an attractive strategy in developing new cancer therapeutics. 7 Recently, RRMs have been considered for drug design approaches. 11, 14 Some compounds have been reported to target RRM1 and RRM2. 13, 24, 25 In addition, compounds targeting RRM3 have been reported. 14, 24 However, the clinical application of these compounds as anticancer drugs will require a long time. To shorten the time until the clinical application of HuR-targeted drugs, drug repositioning from an approved drug is effective. 26 In the present study, we screened an approved drug library using differential scanning fluorimetry (DSF) to identify a HuR-targeted compound. We identified suramin as a suitable candidate that bound to HuR and inhibited HuR function in HSC-3 and SAS cells, a tongue carcinoma cell line. Given its potential to be used clinically, suramin activities were further evaluated in this study. Figure S1 ). 
| MATERIALS AND METHODS

| Expression and purification of
| Differential scanning fluorimetry (DSF)
| Surface plasmon resonance (SPR)
The SPR experiment was performed on a BIACORE T200 instrument (GE Healthcare) equipped with a CM5 sensor chip. The sensor chip was activated via an amine-coupling reaction with EDC and NHS. Then, HuR protein (36 kD) was applied to a flow cell with 10 mmol/L HEPES buffer at pH 7.0. HuR protein was immobilized at a density of 483 RU (response units). The surface was blocked with 1 mol/L ethanolamine hydrochloride at pH 8.5. To collect kinetic binding data, suramin in 10 mmol/L HEPES and 150 mmol/L NaCl (pH 7.4) was injected into the flow cell at the indicated concentrations at 25°C. 
| Cells
| Real-time quantitative reverse transcription PCR (real-time qRT-PCR)
qRT-PCR was performed on cells treated with different concentrations (0, 20, 50, and 100 μmol/L) of suramin for 24 hours in DMEM without FBS. Total cellular RNA was isolated using TRI reagent (Molecular Research Center, Inc, Montgomery Rd, OH, USA) according to the manufacturer's protocol. Selected total RNA samples (1 μg) were reverse-transcribed using ReverTra Ace (Toyobo, Osaka, Japan). CFX96 Real-Time PCR Detection System (Bio-Rad) and the SSO Advanced™ Universal CYBR Green Supermix (Bio-Rad) were used for qRT-PCR. cDNA was amplified using the following primers: for cyclin A2: 5′-AGCTGCCTTTCATTTAGCACTC-3′, 5′-TGCTTTGAGGTAGGTCTGGTG-3′;forcyclinB1: 5′-TGTGGATGCAG-AAGATGGAG-3′, 5′-AACCGA TCAATAATGGAGACAG-3′;for c-fos:5′-CCAACCTGCT GAAGGAGAAG-3′, 5′-GCTGCTGATGCTCTTGACAG-3′;forc-myc:5′-CTCCTGGCAAAAGGTCAGAG-3′, 5′-TC GGTTGTTGCT-GATCTGTC-3′;for COX-2:5′-TGAGCAT CTACGGTTTGCTG-3′,5′-TGC-TTGTCTGGAACAACTG C-3′;forcdk1:5′-TTCAGGATGTGCTTATGCAG-GA-3′,5′-AGTGACAAAACACAATCCCCTGTAG-3′and for GAPDH: 5′-ATCCTGGGCTACACTGAGCA-3′, 5′-TGCTGTAGCCAAATTCGTTG-3′. GAPDH was used for normalization. Relative quantification was performed using the 2 −ΔΔCt method.
To evaluate the half-life of total ARE-mRNA, both control cells and 50 μmol/L suramin-treated cells were treated with 5 μg/mL actinomycin d-mannitol (Sigma) for 2 or 4 hours. The RNA extracted after treatment with actinomycin d-mannitol was subjected to qRT-PCR.
| MTS assay
The CellTiter 96R Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) was used to detect the viable cells in the proliferation and cytotoxicity assay. HSC-3 cells (5 × 10 3 ) were harvested in 96-well plates. After 24 hours, the culture medium was discarded and the cells were washed in phosphatebuffered saline (PBS). Then, DMEM without FBS containing suramin at various concentrations (0, 5, 10, 20, 50, 75, 100, 200, 400, 600, 800, and 1000 μmol/L) was added to the wells. After 24 hours, MTS reagents were added for 4 hours, and the absorbance at optical density (OD) 490 nm was recorded using a microplate reader (Bio-Rad). 
| Wound healing assay
HSC
| In vitro invasion assays
Corning Biocoat Matrigel Invasion Chamber (Corning, Two Oak Park, MA, USA) was used for the invasion assays. HSC-3 and SAS cells were washed in PBS and then suspended in DMEM without FBS. The cells (1.0 × 10 5 ) were added to the upper chamber. The lower chamber was filled with 0, 20, 50, and 100 μmol/L of suramin in DMEM without FBS. After incubation for 24 hours, the cells were fixed with 10% formaldehyde neutral buffer solution (Sigma) for 20 minutes at room temperature, before being stained with crystal violet (0.05% in distilled water) (Katayama Chemical, Osaka, Japan) for 10 minutes. The invading cells were counted using an inverted OLYMPUS CKX41 microscope at ×40 magnification.
| Statistics
Statistical analyses of significance were performed using unpaired Student's t test for comparison between two groups (control vs suramin treatment). The results are shown as the mean ± SD; P < 0.05 was considered statistically significant.
| RESULTS
| Screening of the approved drug library for targeting of HuR by DSF
To identify HuR-interacting compounds, we screened 1570 compounds in the approved drug library by DSF. The compounds were used at 200 μmol/L for HuR (5 μg) in the first DSF. The T m of 55 compounds was shifted by more than 1.0°C positively or negatively ( Figure 1A) . The concentration-dependent thermal shift of T m was confirmed for 55 compounds. The compounds were used at 467 μmol/L for HuR (5 μg) in the second DSF. The shift in the T m of eight compounds was more than that in the first DSF (2.0°C positively or negatively; Figure 1B ). Eight compounds of irregular waveform were excluded. Only suramin showed a positive shift; all other compounds (antibiotics, surface acting agent, hormone, etc) showed a negative shift ( Figure 1C) . Furthermore, to confirm HuR interaction of suramin, DSF was performed at each concentration of suramin. The difference in T m was the highest from 20 μmol/L to 50 μmol/L, and the T m at 100 and 500 μmol/L was almost the same ( Figure  1D ). These data show that suramin interacted with HuR in a concentration-dependent manner.
| Suramin binds to HuR on SPR
SPRis label-free and enables real-time quantification of ligand-binding affinities and kinetics. 28 We performed SPR to evaluate the ligand-binding affinities and kinetics between suramin and HuR. The SPR data are shown in Figure 2 . The binding interaction between suramin and HuR was concentration-dependent. The KD value (2.4 × 10 −4 mol/L) was obtained from the steady-state phase data. The sensorgrams showed square wave appearance, which shows that the interactions reached a steady state rapidly upon injection and also showed rapid dissociation from the binding site. Moreover, the sensorgrams exhibited fast-on and fast-off kinetic behavior. 29 These results show that suramin binds to HuR, but with low affinity.
| Suramin inhibits HuR functions
HuR knockdown decreases the expression and stabilization of ARE-mRNA such asc-fos, c-myc, and COX-2, and mRNAs not containing ARE such as cdk1 and c-fms. 7, 17, 30 The expression and stabilization of these mRNAs decreased when suramin inhibited HuR function. To confirm the expression of ARE-mRNAs such as c-fos, c-myc, COX-2, cyclin A2, and cyclin B1, and mRNAs not containing ARE such as cdk1, we performed qRT-PCR on HSC-3 and SAS cells treated with different concentrations of suramin. The expression of all mRNAs decreased in HSC-3 cells. A significant decrease was observed in the expression of COX-2, cyclin A2, and cyclin B1. The expression of cdk1 showed a slight decrease ( Figure 3A) . Similarly, the expression of all mRNAs except COX-2 decreased in SAS cells. A significant decrease was observed in the expression of c-fos, cyclin A2, and cyclin B1. However, the expression of COX-2 increased in SAS cells ( Figure 3B ). Suramin did not decrease the binding of all mRNA to HuR. It showed different effect in different cell lines, such as on COX-2 levels. Furthermore, to confirm the stabilization of ARE-mRNA, we determined the half-life (t 1/2 ) of cyclin A2 and cyclin B1 mRNA in the control-and suramin-treated cells. The expression of cyclin A2 and cyclin B1 mRNA was estimated at 0, 2, and 4 hours after treatment with actinomycin D (an inhibitor of RNA polymerase II) by qRT-PCR, and the half-life of these mRNAs was calculated ( Figure 3C,D) . In suramin-treated HSC-3 cells, the half-life of cyclin A2 and cyclin B1 mRNA was 3.32 and 2.52 hours, respectively, whereas in the control cells, the half-life was 4.97 and 3.10 hours, respectively ( Figure  3C ). In suramin-treated SAS cells, the half-life of cyclin A2 and cyclin B1 mRNA was 3.78 and 3.29 hours, whereas in the control cells, the half-life was 4.03 and 3.35 hours, respectively ( Figure 3D ). To confirm that HuR overexpression inhibits decrease in expression of ARE-mRNA for treatment of suramin, we performed to transfection in the HSC-3 cells with plasmid of pcDNA3 or pcDNA3-HuR and treatment of difference concentration of suramin. Though it is no significant difference, decrease rate of expression of the cyclin A2 and cyclin B1 mRNA in the suramin-treated cells for the Error bars, SD. Student's t test, *P < 0.05, **P < 0.01, ***P < 0.001 control cells was smaller in the cells transfected pcDNA3-HuR than in the cells transfected control plasmid ( Figure  S2 ). Next, to confirm the location of HuR, we performed immunofluorescence staining. Suramin did not change the localization of HuR ( Figure S3 ). These data indicate that suramin decreases the expression and stabilization of AREmRNA but does not affect nucleo-cytoplasmic transport, suggesting that suramin inhibits HuR functions, such as mRNA binding. 
| Suramin decreased the levels of proteins translated from ARE-mRNA
We performed Western blotting to confirm whether the levels of proteins translated from ARE-mRNA decreased in suramin-treated HSC-3 cells. COX2, cyclin A2, and cyclin B1 protein levels decreased in suramin-treated cells compared with the control cells ( Figure 4 ). Suramin did not decrease the HuR protein level (Figure 4 ). These results indicate that suramin decreased COX-2, cyclin A2, and cyclin B1 protein levels to inhibit HuR functions, such as mRNA stabilization.
| Suramin decreases cell viability in a concentration-dependent manner
MTS assay was performed to confirm the cytotoxicity of suramin against HSC-3 cells. Although suramin decreased the viability of HSC-3 cells in a concentration-dependent manner, it showed low cytotoxicity (IC 50 of suramin = 732 µmol/L). The cell viability at the highest treated concentration of suramin (1000 µmol/L) was 42% ( Figure 5 ). These results suggest that suramin exhibited low cytotoxicity and did not induce necrosis strongly.
| Suramin attenuated motile and invasive activities of HSC-3 and SAS cell line
In our previous report, we showed that HuR knockdown attenuates motile and invasive activities. 7 We presumed that suramin attenuates the motile and invasive activities of HSC-3 and SAS cells as well as HuR knockdown HSC-3 cells. To prove this, wound healing and invasion assays were performed. HSC-3 and SAS cells treated with each concentration of suramin were scratched and observed after 12, 24, and 48 hours. At a concentration of 35 µmol/L or above, suramin suppressed the motile activity of HSC-3 cells significantly (P < 0.05 or 0.01; Figure 6A ,B). At a concentration of 50 µmol/L or above, suramin suppressed the motile activity of SAS cells significantly (P < 0.05 or 0.01; Figure 6A ,B). Next, HSC-3 and SAS cells were seeded in invasion chambers containing Matrigel-coated membranes, and the lower chamber was filled with different concentrations of suramin. Treatment of HSC-3 cells with suramin at concentrations above 50 µmol/L strongly suppressed the invasive activity compared to control cells (P < 0.05; Figure 6C ). Suramin (20 µmol/L) tended to suppress the invasive activity of HSC-3 cells (P = 0.051).
Treatment of SAS cells with suramin at 100 µmol/L strongly suppressed the invasive activity as compared to control cells (P < 0.05; Figure 6C ). These results suggest that suramin strongly attenuated the motile and invasive activities and thus the malignant phenotype of HSC-3 and SAS cells.
| DISCUSSION
In this study, we screened 1570 compounds in the approved drug library by DSF and selected suramin as a potential HuR-targeted anticancer drug. Suramin exhibited anticancer effects by inhibiting HuR function in HSC-3 cells. HuR binds and stabilizes the ARE-mRNA-related malignant phenotype, such as proliferation, invasion, and metastasis. 3 In our previous studies, 7, 17 we showed that
HuR was expressed abundantly in oral cancer cells, and HuR knockdown attenuated the malignant phenotype of these cells. Therefore, HuR-targeted compounds that inhibit HuR functions such as ARE-mRNA stabilization can be used as novel anticancer agents. Recently, certain HuR inhibitors were reported, such as MS-444, 13 quercetin, 27 azaphilone-9, 24 and some other small molecule compounds. 14, 25 As HuR inhibitors are still in the initial stages of development, it will take a long time to reach the clinical trial stage. Drug development is time-consuming and expensive. However, repositioning of approved drugs can function more efficiently and minimize the costs and risks compared to experimental drug development from the start. 26 Pharmakon-1600 is an approved drug library, which combines US drug collection and international drug collection. The US drug collection comprised FDA approved drugs. The international drug collection is used in Europe and Asia, but not approved for use in the United States. Therefore, we chose the approved drug library to screen compounds.
We used DSF for identifying HuR-interacting compounds in the library. DSF is a high-throughput and inexpensive screening method to identify low-molecular-weight ligands that bind and stabilize purified proteins. 31 In the first and second DSF, eight compounds were selected from 1570 compounds ( Figure 1A,B) . Only suramin shifted the T m positively in a concentration-dependent manner ( Figure 1C,D) . In most cases, if a compound binds to a protein, the free energy contribution of ligand-binding results in an increase in Gibbs free energy of unfolding, and this might cause an increase in T m . The stabilizing effect of compounds on binding is proportional to the concentration and affinity of the ligands. 31 The results of DSF suggest that suramin interacts and binds to HuR. We performed SPR to confirm the affinities and kinetics between suramin and HuR. As shown by SPR, suramin binds to HuR, exhibiting fast-on and fast-off kinetic behavior. Therefore, we selected suramin as a potential HuR inhibitor. Suramin is a polysulfonated naphthylurea introduced in the 1920s for the treatment of African trypanosomiasis and onchocerciasis by inhibiting DNA polymerases and reverse transcriptase. At the end of the 1970s, it was found to competitively inhibit retroviral reverse transcriptase. 32 Since the late 1980s, the activity of suramin as an anticancer agent in hormone-refractory prostate cancer (HRPC) patients has been appreciated. 33, 34 Suramin exerts antitrypanosomal, anticancer, and antiviral activities. [32] [33] [34] [35] It is capable of blocking the binding of growth factors, such as EGF, TGF-β, PDGF, bFGF, and VEGF, to their surface receptors. 33, [36] [37] [38] In addition, suramin decreases the expression of cell proliferation markers such as cyclin A, cyclin D1, and cyclin E, arrests cells in G1, and decreases the number of cells in S-phase moderately. 35 However, the degree to which the anticancer effects of suramin are mediated by the above mechanisms is unclear. We presumed that the anticancer effects of suramin are caused by the inhibition of HuR function and confirmed that suramin decreases the expression and stabilization of HuR-binding mRNA ( Figure 3A ). Cdk1 expression was slightly decreased compared to that of other mRNAs in HSC-3 cells. COX-2 expression significantly decreased in HSC-3 cells, but increased in SAS cells. Similarly, suramin treatment showed different effects on ARE-mRNA in different cell lines. We found that suramin decreased the protein levels of COX-2, cyclin A2, and cyclin B1 in HSC-3 cells (Figure 4 that translated from HuR-binding ARE-mRNA. 3 HuR knockdown led to G1 arrest 39 in cancer cells as well as suramintreated cells, 35 because HuR regulates cell cycle through stabilization of cell cycle-related ARE-mRNA. 40, 41 These reports suggested the association between suramin and HuR. Recently, it was reported that suramin improved language and social interaction, and decreased restricted or repetitive behaviors of autism spectrum disorder (ASD). 42 However, the mechanism underlying the effects of suramin in ASD is unclear. HuR regulated the translation of mRNA transcribed from autism-associated genes, Foxp1 and Foxp2. 43 Suramin may have improved ASD by inhibiting HuR-Foxp1 and/or HuR-Foxp2 binding. Thus, from these findings, it can be suggested that suramin inhibits HuR functions. Noncytotoxic concentration of suramin was found to be less than 50 µmol/L, whereas it showed high cytotoxicity at concentrations more than 200 µmol/L. 44 Effective plasma concentration of suramin was reported to be between 100 and 200 µmol/L. 45 Therefore, MTS, wound healing, and invasion assays were performed to find the concentration of suramin that affects the malignant phenotype of oral cancer cells. In MTS assay, suramin did not induce cell death strongly at low-moderate concentrations (<100 µmol/L). However, lowmoderate concentrations of suramin (50 and 100 µmol/L) attenuated motile and invasive activities markedly in HSC-3 cells with high metastatic potential. Suramin at 100 µmol/L attenuated these activities in SAS cells. These results showed that low-moderate concentration of suramin exhibits low cytotoxicity, but affects motile and invasive activities strongly in oral cancer cells. Large clinical trials of suramin for cancer have been reported previously. A double-blind placebo-controlled phase III trial was undertaken to evaluate the efficacy of suramin plus hydrocortisone (HC) in patients with symptomatic HRPC. 34 The adrenal suppressive properties of suramin require the concomitant administration of HC. Compared to patients who received placebo plus HC, those who received suramin plus HC showed delayed disease progression, decline in prostate-specific antigen (PSA), and effective reduction of pain. In the trials, most adverse events were mild or moderate intensity and easily managed medically. The suppression of disease progression and reduction of pain can be explained by the decrease in cyclin-related and COX-2 protein levels in HSC-3 cells by suramin. Although suramin has not been used for the treatment of oral cancer, our results suggest that suramin can suppress disease progression and invasion and may reduce pain by decreasing COX-2 protein levels depending on cell line. Oral cancer leads to poor quality of life due to intense pain and significantly impairs speech, swallowing, and masticatory functions. 46 Oral cancer pain management is difficult. Therefore, suramin, which reduces pain, can be used effectively for oral cancer therapy.
Our study had some limitation. Firstly, higher affinity is ideally preferred for an HuR inhibitor; however, suramin binds to HuR with low affinity (KD value 2.4 × 10 −4 mol/L).
Secondly, cells were treated with suramin in the absence of serum to exclude the effect of other serum components. Thirdly, suramin has been reported to have anticancer effects in vivo, but we could not report whether suramin could inhibit HuR function in vivo.
In conclusion, in this report, we show that suramin binds to HuR and inhibits HuR functions such as AREmRNA stabilization and translation. In addition, suramin markedly attenuates the malignant phenotype of HSC-3 and SAS cells. Therefore, suramin, a HuR-targeted drug, has potential as a new therapeutic agent for oral cancer therapy. Our results suggest that suramin, via its different mechanism, may effectively suppress progressive oral cancer that cannot be controlled using other anticancer agents.
